Bevacizumab was one of the classical molecularly targeted drugs against vascular endothelial growth factor (VEGF), which has been used in treatment for various cancers such as metastatic colorectal cancer, non-small cell lung cancer and breast cancer (Zhu et al., 2007). The gene discussed is VEGFA; the disease is breast cancer.